A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to estimate the response rate to ALKS 4230 in
combination with pembrolizumab in patients with HNSCC who have previously received
anti-PD-(L)1 therapy but who have not achieved a CR.